HHLR Advisors’s Aligos Therapeutics ALGS Stock Holding History

HHLR Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$440K	Hold	76,247	–	–	0.05%	34
2026 Q1	$567K	Hold	76,247	–	–	0.03%	35
2025 Q4	$711K	Hold	76,247	–	–	0.02%	29
2025 Q3	$747K	Hold	76,247	–	–	0.02%	31
2025 Q2	$550K	Hold	76,247	–	–	0.02%	33
2025 Q1	$629K	Hold	76,247	–	–	0.02%	44
2024 Q4	$3.04M	Hold	76,247	–	–	0.11%	26
2024 Q3	$660K	Sell	76,247 -48,621	-39%	-$605K	0.01%	44
2024 Q2	$1.09M	Buy	124,868 +48,620	+64%	+$855K	0.03%	70
2024 Q1	$1.87M	Hold	76,248	–	–	0.04%	51
2023 Q4	$1.27M	Sell	76,248 -16,143	-17%	-$278K	0.03%	42
2023 Q3	$1.73M	Hold	92,391	–	–	0.04%	51
2023 Q2	$2.24M	Hold	92,391	–	–	0.05%	49
2023 Q1	$2.02M	Hold	92,391	–	–	0.04%	61
2022 Q4	$2.2M	Sell	92,391 -2,212	-2%	-$55.8K	0.05%	57
2022 Q3	$2.6M	Hold	94,603	–	–	0.07%	49
2022 Q2	$2.86M	Hold	94,603	–	–	0.06%	54
2022 Q1	$5.08M	Hold	94,603	–	–	0.11%	44
2021 Q4	$28.1M	Hold	94,603	–	–	0.43%	32
2021 Q3	$36.7M	Buy	94,603 +8,000	+9%	+$3.16M	0.48%	31
2021 Q2	$44.1M	Hold	86,603	–	–	0.45%	33
2021 Q1	$49.2M	Hold	86,603	–	–	0.49%	30
2020 Q4	$59.9M	Buy	+86,603	New	+$42.2M	0.48%	30

Other funds holding ALGS

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HHLR Advisors's ALGS Position: Q2 2026 in Review

HHLR Advisors held its Aligos Therapeutics (ALGS) position steady in Q2 2026 at 76,247 shares worth $440K. The position accounts for 0.05% of the portfolio, ranked #34.

HHLR Advisors first reported a position in ALGS in Q4 2020 and has held it in 23 quarters since. The position peaked at $59.9M in Q4 2020. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

HHLR Advisors held 76,247 shares of Aligos Therapeutics worth $440K as of Q2 2026.
HHLR Advisors left its Aligos Therapeutics share count unchanged in Q2 2026.
Aligos Therapeutics made up 0.05% of HHLR Advisors's portfolio in Q2 2026, its #34 holding.
HHLR Advisors first reported a position in Aligos Therapeutics in Q4 2020 and has held it in 23 quarters since.
HHLR Advisors's Aligos Therapeutics position peaked at $59.9M in Q4 2020.
31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on HHLR Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.